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Abstract
Background: To support the development of global strategies against breast cancer, this study reviews available
economic evidence on breast cancer control in low- and middle-income countries (LMICs).
Methods: A systematic article search was conducted through electronic scientific databases, and studies were
included only if they concerned breast cancer, used original data, and originated from LMICs. Independent
assessment of inclusion criteria yielded 24 studies that evaluated different kinds of screening, diagnostic, and
therapeutic interventions in various age and risk groups. Studies were synthesized and appraised through the use
of a checklist, designed for evaluating economic analyses.
Results: The majority of these studies were of poor quality, particularly in examining costs. Studies demonstrated
the economic attractiveness of breast cancer screening strategies, and of novel treatment and diagnostic
interventions.
Conclusions: This review shows that the evidence base to guide strategies for breast cancer control in LMICs is
limited and of poor quality. The limited evidence base suggests that screening strategies may be economically
attractive in LMICs – yet there is very little evidence to provide specific recommendations on screening by
mammography versus clinical breast examination, the frequency of screening, or the target population. These
results demonstrate the need for more economic analyses that are of better quality, cover a comprehensive set of
interventions and result in clear policy recommendations.
Keywords: Breast cancer control, Economic evaluation, Systematic review, Low- and middle-income countries,
Cost-effectiveness, Noncommunicable diseases
Background
Noncommunicable diseases (NCDs) have become increas-
ingly important in low- and middle-income countries
(LMICs). Once considered a problem only in high-income
countries (HICs), more and more patients who suffer from
cancers and other NCDs are now observed in LMICs [1].
This is mainly due to the ageing populations and changing
lifestyles in LMICs [2]. The global importance of NCDs has
recently been acknowledged through the UN Summit on
NCDs, held by the UN General Assembly in September
2011. As highlighted in the summit, the most prominent
cause of cancer death among women in LMICs is
breast cancer, accounting for 269,000 deaths (12.7% of
all cancer deaths) in 2008 [3,4].
In HICs, many efforts have been undertaken to control
breast cancer, leading to various improvements in breast
cancer outcomes [5,6]. Strategies for breast cancer
control are geared towards early detection and early
treatment, and although its benefits are still open to dis-
cussion [7-9], mammography screening has been widely
implemented [10-12]. In these countries, the selection of
breast cancer control strategies has often been guided by
economic analyses, demonstrating the value of alternative
interventions [13-16].
In contrast to the established breast cancer control
strategies in HICs, breast cancer is often neglected in
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LMICs and control strategies lack evidence-based infor-
mation [17-20]. Policy-makers in LMICs cannot adopt
similar breast cancer control strategies as implemented in
HICs because most LMICs rely on much smaller budgets,
and both the costs and effectiveness of control strategies
are highly dependent on the population characteristics
and the functioning of the health system [11,20,21].
Against this background, the present review provides
an inventory of economic analyses of breast cancer
control in LMICs. The paper’s objectives are to present
the available economic evidence from LMICs and to
assess the methodological quality of the analyses. This
research could improve the evidence base on cost-effective
breast cancer interventions and could strengthen breast
cancer control policy in LMICs.
Methods
Search strategy and selection criteria
In this review, we analyzed publications from the
MEDLINE index using PubMed, the Web of Science,
Scopus, and Google Scholar. We searched the literature
using the keyword ‘breast cancer’, combined with the
keywords: ‘developing countries’, ‘Asia’, ‘USSR’, ‘Middle-
East’, ‘Eastern Europe’, ‘West-Indies’, ‘China’, ‘Russia’, ‘India’,
‘Africa’, or ‘limited resource’, or combined with: ‘cost-benefit’,
‘cost-effectiveness’, ‘costing’, or ‘cost analysis’. Additionally,
we searched these indexes using ‘breast neoplasms’,
‘developing countries,’ and ‘economics’ in MeSH terms.
Our search took place in January 2013, and was limited to
publications in English. Studies were included only if they
concerned breast cancer and originated from LMICs as
listed by The World Bank [22].
The selection process is shown in Figure 1. In step 1,
articles found by our search in the various indexes
were merged in a database, which was then corrected
for duplications (in Google Scholar, because of the
large number of articles founds, we screened titles
until the point that we did not find any further relevant
title among the last 500 screened titles; in total, we
screened 800 titles in this database). In step 2 we
screened the titles of these articles, in step 3 the
abstracts and in step 4 the remaining articles were read
completely. We excluded publications for which no
full-text article versions were available, or those not
published in English. Furthermore, we excluded articles
that only mentioned costs or cost-effectiveness without
presenting original data.
Study characteristics
We documented the following characteristics from the
reviewed articles: country or region, base year of cost data,
study population, and breast cancer stage(s) considered.
The stage was categorized as stage I to IV according to the
American Joint Committee on Cancer [23].
We documented the following methodological char-
acteristics: type of economic evaluation –cost analysis
or cost of illness analysis, separately reported costs and
effects, cost-effectiveness analysis, cost–benefit analysis,
and cost–utility analysis; study design – experimental,
observational (cohort, case control, or cross-sectional),
model based, and other designs; study perspective –
non-healthcare perspective (for example, productivity
loss, travel costs, co-payments), healthcare perspective
(for example, hospital administration costs, treatment costs),
and societal perspective including non-healthcare and
healthcare costs; time horizon; and outcome measure
for effectiveness (disability-adjusted life years, quality-
adjusted life years, life years saved, lives saved, and
intermediate outcome measures).
The following qualitative characteristics were docu-
mented: sources for estimation of effectiveness, sources
for estimation of resource utilization, discount rates
used, sensitivity analysis for assumptions, and reported
incremental analysis. We classified sources for estimation
of effectiveness and resource utilization by primary data
collection (for example, patients, questionnaires), secondary
data collection (for example, records), literature based,
expert opinion, and other. We also noted whether discount
rates were used on costs, effects, both costs and effects, or
not at all.
We also registered the study objective, the evaluated
interventions, and the main study conclusions for each
reviewed article.
Study evaluation
We used an established checklist by Drummond and
Jefferson to judge the quality of the economic evaluations
[24,25]. A three-point response scale was added, similar to
Gerard and colleagues [25], to more specifically grade the
quality of each item on the checklist. Scores on this scale
ranged from 0 (not considered), to 1 (partially considered)
to 2 (fully considered). A few adjustments to the checklist
by Drummond and Jefferson were necessary to create a
more responsive scoring system for our particular set of
economic studies. We removed those items that were not
applicable to any of the reviewed studies (for example, on
productivity changes), and combined some items that
were otherwise putting too much emphasis to certain
domains in the overall score (for example, on health state
valuations and discount rates). The adapted checklist is
provided in Table 1. We summed up all scores, and
compared this with the maximum attainable score to
calculate the mean quality score of a study (as a percentage
of the maximum attainable score). We accounted for
items that were not relevant to the study under scrutiny
(for example, studies that studied costs and effects in
a single year were not criticized for not applying any
discount rate in the analyses).
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Two reviewers (SGZ and RMB) evaluated each publica-
tion for conformance with this checklist, and consensus
was reached when scores differed. We followed PRISMA
guidelines for reporting this systematic review.
Results
Search results
The stepwise selection of articles by our selection cri-
teria is presented in Figure 1. Our search strategy
resulted in a total of 6,816 studies: 679 studies from
PubMed, 328 studies from Web of Science, 5,009 stud-
ies from Scopus, and 800 from Google Scholar, re-
spectively. In step 1, by merging the results of all
individual search strategies and excluding duplication,
the total number of hits was reduced to almost 4,400.
Upon screening of titles (step 2), abstracts (step 3) and
full texts (step 4), we eventually identified 24 articles
that met our inclusion criteria.
Study characteristics
Table 2 describes the baseline characteristics of the 24
included studies. We found eight studies from Asia,
most concerning China, India and Iran. Five studies
were on a global or sub-regional level, while there were
five studies from Africa, three from Europe and three
from Latin America. A total of 10 studies evaluated
breast cancer screening in combination with treatment
(n = 10), assessing mammography screening (n = 9), clinical
breast examination (CBE) (n = 3), magnetic resonance
imaging (n = 1), ultrasound (n = 1), biopsy (n = 1), elasticity
imaging (n = 1), and tactile imaging (n = 1), respectively
[26-36]. These studies evaluated a variety of age groups
and screening frequencies (Table 3). One study reported
on a mass-media intervention to improve the early
detection of breast cancer in Ghana [35]. Seven studies
evaluated only treatment interventions including drug
therapy (n = 4), oophorectomy (n = 1), radiotherapy
(n = 1), and treatment in general (n = 1) [37-42].
Other studies examined the costs of diagnostic inter-
ventions (n = 3) or did not consider a specific intervention
(n = 2) [43-48].
The methodological study characteristics of the reviewed
studies are presented in Table 2. The base year of cost data
in the included studies was generally not from before year
2000, and could not be identified in eight studies. The
majority of studies combined both costs and effects in a
Figure 1 Prisma statement 1: Prisma 2009 flow diagram.
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single cost-effectiveness estimate (n = 13), and the majority
of these were based on mathematical models (n = 9). Most
studies used a healthcare perspective (n = 19), and only one
study included non-healthcare costs [48]. Studies used a
time horizon varying between 5 weeks and the lifetime of
the study population. Most reviewed studies used inter-
mediate outcome measures (that is, clinical effects n = 8),
life years saved (n = 6), or disability-adjusted life years
(n = 5) as their main effectiveness outcome, while quality-
adjusted life years were less frequently used (n = 3).
Table 1 Checklist for quality of economic evaluations
Item Fully Partial Not at all Not appropriate
Original checklist 2 points 1 point 0 points NA
Study design
1. The research question is stated □ □ □ □
2. The economic importance of the research question is stated □ □ □ □
3. The viewpoint(s) of the analysis are clearly stated and justified
(relating to a particular decision-making context)
□ □ □ □
4. The rationale(s) for choosing the alternative programs or interventions which
are compared is stated
□ □ □ □
5. The alternatives being compared are clearly described □ □ □ □
6. All relevant alternatives are included □ □ □ □
7. The choice of economic evaluation is justified in relation to the questions addressed □ □ □ □
Effectiveness estimation
8. The primary outcome measure for the economic evaluation is clearly stated □ □ □ □
9. The source(s) of effectiveness estimates used is clearly stated □ □ □ □
10. Details of the design and results of the effectiveness study are given
(if based on a single study)
□ □ □ □
11. Details of the methods of synthesis or meta-analysis of estimates are given
(if based on multiple studies)
□ □ □ □
12. Data and methods used to value health states and other benefits are stated and justified. □ □ □ □
Cost estimation
14. Indirect non-healthcare costs are included or discussed □ □ □ □
15. Quantities of resources are reported separately from their unit costs □ □ □ □
16. Methods for the estimation of quantities and unit costs are described and justified. □ □ □ □
17. Details of currency of price adjustments for inflation or currency conversion are given □ □ □ □
Analysis
18. Time horizon of costs and benefits are stated □ □ □ □
18. Details of any model used are given □ □ □ □
19. The choice of model used and the key parameters on which it is based are justified □ □ □ □
20. The discount rate(s) is stated □ □ □ □
21. The choice of rate(s) is justified □ □ □ □
22. Details of statistical tests and confidence intervals are given for stochastic data □ □ □ □
23. Sensitivity analysis is performed: 2) Probabilistic (bootstrap/Monte Carlo)
1) Deterministic (one way /multiple way)
□ □ □ □
24. The choice of variables in sensitivity analysis and the range over which these variables
are varied is justified
□ □ □ □
25. Incremental analysis is performed and reported □ □ □ □
Interpretation of results □ □ □ □
26. Major outcomes are presented in a disaggregated as well as aggregated form □ □ □ □
27. The answer to the study question is given □ □ □ □
28. Relevant alternatives are compared □ □ □ □
29. Conclusions follow from the data reported □ □ □ □
30. Conclusions are accompanied by the appropriate caveats such as generalizability,
equity, feasibility, and implementation
□ □ □ □
This checklist was adapted from Drummond and Jefferson [24].
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Table 2 Characteristics of reviewed studies, ordered by base year of cost data
Authors Region /
country
Base year
of cost data
Study population Breast
cancer
stage
considered
Economic
evaluation
type
Study design Perspective
Groot and
colleagues, 2006 [28]
World
sub-regions
2000 Female population at risk,
in AfrE, AmroA, SearD
All Cost-effectiveness
analysis
Model based Healthcare
Okonkwo and
colleagues, 2008 [30]
India 2001 Female population at risk All Cost-effectiveness
analysis
Model based Healthcare
Munshi, 2009 [41] Worldwide Varying from
2002 to 2007
Breast cancer patients
in general
All Report on costs and
effects separately
Other Healthcare
Sarvazyan and
colleagues, 2008 [32]
Worldwide Varying from
2003 to 2007
Female population at risk All Cost-effectiveness
analysis
Other Not stated
Fonseca and
colleagues, 2009 [38]
Brazil 2005 Hypothetical cohort of 64-
year-old postmenopausal
women
All Cost-effectiveness
analysis
Model based Healthcare
Ginsberg and
colleagues, 2012 [27]
Sub-Saharan
Africa and
South East Asia
2005 Female population at risk,
in SearD and AfrE
All Cost-effectiveness
analysis
Model based Healthcare
Salomon and
colleagues, 2012 [31]
Mexico 2005 Female population at risk All Cost-effectiveness
analysis
Model based Healthcare
Pakseresht and
colleagues, 2011 [48]
India 2006/2007 103 women with primary
breast cancer in a tertiary
hospital
All Cost analysis/cost
of illness
Observational Non-
healthcare
Yazihan and
Yilmaz, 2006 [34]
Turkey 2007 Female population at risk All Cost-effectiveness
analysis
Other Healthcare
Bastani and
Kiadaliri, 2012 [49]
Iran 2008 Patients younger than 75
with node-positive breast
cancer
All Cost-utility analysis Experimental Healthcare
Liubao and
colleagues, 2009 [39]
China 2008 Model cohort of 1,000
51-year-old operable
breast cancer patients
All Cost-effectiveness
analysis
Model based Healthcare
Astim, 2011 [36] Turkey 2010 Female population at
risk older than 30
All Report on costs and
effects separately
Model based Healthcare
Zelle and colleagues,
2012 [35]
Ghana 2010 Female population at risk All Cost-effectiveness
analysis
Model based Healthcare
Bai and colleagues,
2012 [42]
China 2012 Model cohort of women aged
51.7, with early stage breast
cancer after lumpectomy
1 and 2 Cost-effectiveness
analysis
Model based Healthcare
Arredondo and
colleagues, 1995 [43]
Brazil Not clear Hypothetical breast
cancer case
All Cost analysis/cost
of illness
Observational Healthcare
Boutayeb and
colleagues, 2010 [37]
Morocco Not clear Early-stage breast cancer
patients in Morocco
Not clear Cost-effectiveness
analysis
Observational Healthcare
Denewer and
colleagues, 2010 [26]
Egypt Not clear Female population at risk
between 25 and 65 years
All Report on costs and
effects separately
Experimental Healthcare
Guggisberg and
colleagues, 2011 [46]
Cameroon Not clear Women who underwent
FNA in a rural hospital
All Report on costs and
effects separately
Observational Healthcare
Kobayashi, 1988 [44] Worldwide Not clear NA NA Cost analysis/cost
of illness
Observational Healthcare
Love and colleagues,
2002 [40]
Vietnam
and China
Not clear Premenopausal Vietnamese
and Chinese breast cancer
patients, considered for surgery
2 Cost-effectiveness
analysis
Experimental Healthcare
Mousavi and
colleagues, 2008 [29]
Iran Not clear Female population at
risk between 35 and 69
All Report on costs and
effects separately
Other Healthcare
Nasrinossadat and
colleagues, 2011 [47]
Iran Not clear 51 patients that underwent
surgical excision of
nonpalpable breast masses
All Report on costs and
effects separately
Observational Healthcare
Thomas and
colleagues, 1999 [45]
Nigeria Not clear Patients who received FNA
between 1994 and 1997
All Report on costs and
effects separately
Observational Patient
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Table 2 Characteristics of reviewed studies, ordered by base year of cost data (Continued)
Authors Perspective Time
horizon
Effectiveness
outcome
measure
Sources for
estimation of
effectiveness
Sources for
estimation
of resource
utilization
Discount
rates used
Sensitivity
analysis for
assumptions
presented
Incremental
analysis
reported
Groot and
colleagues, 2006 [28]
Healthcare 100
years
DALYs Literature based Secondary
data collection
On both costs
and effects
Yes Yes
Okonkwo and
colleagues, 2008 [30]
Healthcare 25 years Life years saved Secondary data
collection
Secondary
data collection
On both costs
and effects
Yes Yes
Munshi, 2009 [41] Healthcare NA Intermediate
outcome
measures
Literature based Literature NA NA NA
Sarvazyan and
colleagues, 2008 [32]
Not stated 1 year Life years saved Literature based Literature NA Yes No
Fonseca and
colleagues, 2009 [38]
Healthcare Lifetime Life years saved Literature based Expert opinion On both costs
and effects
Yes Yes
Ginsberg and
colleagues, 2012 [27]
Healthcare 100
years
DALYs Literature based Secondary
data collection
On both costs
and effects
Yes Yes
Salomon and
colleagues, 2012 [31]
Healthcare 100
years
DALYs Literature based Secondary
data collection
On both costs
and effects
Yes Yes
Pakseresht and
colleagues, 2011 [48]
Non-
healthcare
2 years NA NA Primary data
collection
NA NA NA
Yazihan and
Yilmaz, 2006 [34]
Healthcare 6 years DALYs Secondary data
collection
Secondary
data collection
None No No
Bastani and
Kiadaliri, 2012 [49]
Healthcare 8
months
QALYs Primary data
collection
Primary data
collection
NA No NA
Liubao and
colleagues, 2009 [39]
Healthcare Lifetime QALYs Secondary data
collection
Secondary
data collection
On both costs
and effects
Yes Yes
Astim, 2011 [36] Healthcare 10 years Intermediate
outcome
measures
Secondary data
collection
Literature Yes No No
Zelle and colleagues,
2012 [35]
Healthcare 100
years
DALYs Literature based Primary data
collection
On both costs
and effects
Yes Yes
Bai and colleagues,
2012 [42]
Healthcare Lifetime QALYs Literature based Literature/
expert opinion
On both costs
and effects
Yes Yes
Arredondo and
colleagues, 1995 [43]
Healthcare NA NA NA Expert opinion NA No No
Boutayeb and
colleagues, 2010 [37]
Healthcare 1 year Life years saved Literature based Secondary
data collection
NA No No
Denewer and
colleagues, 2010 [26]
Healthcare 2 years Intermediate
outcome
measures
Primary data
collection
Not clear None No No
Guggisberg and
colleagues, 2011 [46]
Healthcare 5 weeks Intermediate
outcome
measures
Primary data
collection
Not clear NA No No
Kobayashi, 1988 [44] Healthcare NA Intermediate
outcome
measures
Primary data
collection
Primary data
collection
NA NA NA
Love and colleagues,
2002 [40]
Healthcare 15 years Life years saved Primary data
collection
Not clear On both costs
and effects
No Yes
Mousavi and
colleagues, 2008 [29]
Healthcare 1 year Life years saved Expert opinion Expert opinion NA No No
Nasrinossadat and
colleagues, 2011 [47]
Healthcare 3 to 4
years
Intermediate
outcome
measures
Primary data
collection
Not clear None No No
Thomas and
colleagues, 1999 [45]
Patient NA Intermediate
outcome measures
Primary data
collection
Not clear NA NA NA
DALYs, disability-adjusted life years; FNA, fine needle aspiration; NA, not applicable; QALYs, quality-adjusted life years.
Zelle and Baltussen Systematic Reviews 2013, 2:20 Page 6 of 13
http://www.systematicreviewsjournal.com/content/2/1/20
Table 3 Interventions compared, study objectives, and main study conclusions of reviewed articles
Authors Interventions compared Study objective Conclusions by authors
Groot and colleagues,
2006 [28]
Combinations of individual stage I to IV
treatment and an extensive mammography
screening control program
To assess the cost-effectiveness of breast
cancer control that covers various
interventions in different settings
Stage I treatment and an extensive
screening control program are the
most cost-effective interventions
Okonkwo and
colleagues, 2008 [30]
Mammography screening, CBE screening
among different age groups and in different
frequencies
To assess which screening program
should be implemented in India
CBE screening in India compares
favorably with mammography
screening in developed countries
Munshi, 2009 [41] Several treatment interventions To present pragmatic cost-saving breast
cancer interventions
Intelligent use of knowledge about
the disease can help us to exploit
new techniques for maximum
therapeutic gain with minimal
investment
Sarvazyan and
colleagues, 2008 [32]
CBE, mammography, ultrasound, magnetic
resonance imaging, biopsy, elasticity
imaging, tactile imaging
To review the diagnostic accuracy,
procedure cost, and cost-effectiveness
of currently available techniques for
breast screening and diagnosis.
Tactile imaging has the potential to
provide cost-effective breast cancer
screening and diagnosis
Fonseca and
colleagues, 2009 [38]
Anastrozole vs. tamoxifen in the adjuvant
setting of early breast cancer
To determine cost-effectiveness of
anastrozole, compared with tamoxifen,
in the adjuvant treatment of early stage
breast cancer in Brazil
Anastrozole is more cost-effective
than tamoxifen in the adjuvant
setting of early breast cancer
Ginsberg and
colleagues, 2012 [27]
Stage 1 to 4 treatment individual, treatment
of all stages, biennial mammography
screening 50 to 70 vs. null scenario
To determine the cost-effectiveness of
81 interventions to combat breast,
cervical and colorectal cancer at
different geographic coverage levels, to
guide resource allocation decisions
in LMICs
For breast cancer, although expensive,
mammography screening in
combination with treatment of all
stages is cost-effective in both regions
(I$2,248 to 4,596/DALY). Treating
early-stage breast cancer is more
cost-effective than treating late-stage
disease
Salomon and
colleagues, 2012 [31]
Stage 1 to 4 treatment individual, treatment
of all stages, screening (annual CBE >25
years + mammography annual >50 years +
mammography biennial >40 to 49 years)
vs. null scenario
Analyze the cost-effectiveness of 101
intervention strategies directed at nine
major clusters of NCDs in Mexico
(including breast cancer), to inform
decision-makers
Treatment of all stages is cost-
effective and treatment of early
stages is more cost-effective than
late stage treatment. Nationwide
screening has an incremental CEA
of I$22,000/DALY and is potentially
cost-effective
Pakseresht and
colleagues, 2011 [48]
NA To estimate the expenditure audit of
women with breast cancer in a tertiary
hospital in Delhi
Expenditure on treatment for breast
cancer depends on many factors,
including the size and stage of the
cancer, the woman's age, use of
private hospitals and insurance
Szynglarewicz and
Matkowski, 2011 [33]
Polish screening program costs vs. other
countries
To show preliminary results of the
Polish screening program
Population-based mammographic
screening conforming the European
quality standards is cost-effective
even for middle-income countries
Yazihan and Yilmaz,
2006 [34]
Mammography screening in age group
50 to 69 vs. treatment only
To determine the efficiency of resource
usage in mammography screenings
and the impact on breast cancer
stages in Turkey
Mammography screening is
economically attractive for Turkey
Bastani and Kiadaliri,
2012 [49]
Docetaxel, doxorubicin and
cyclophosphamide (TAC) vs. 5-fluorouracil,
doxorubicin, cyclophosphamide (FAC) in
node-positive breast cancer patients
To evaluate the cost-utility of TAC
and FAC in node-positive breast
cancer patients
FAC was a dominant option versus
TAC in the short term. In this study,
TAC resulted in higher costs and
lower QALYs over the study period
Liubao and
colleagues, 2009 [39]
AC (doxorubicin/cyclophosphamide) vs. TC
(docetaxel/cyclophosphamide)
To estimate the cost-effectiveness of
AC (doxorubicin/cyclophosphamide)
vs. TC (docetaxel/cyclophosphamide)
TC appears to be more effective
and more costly than AC. TC may
be viewed as cost-effective using
the general WHO threshold
Astim, 2011 [36] Annual and biennial mammography
screening in various age groups
(40+, 45+, 50+, 55+, 60+ years) vs.
no screening
To evaluate the cost-effectiveness, optimal
minimum age and screening interval for a
screening program in Turkey
Results of the simulation suggests
that women over 40 in Turkey
should be screened by
mammography biennially
Zelle and colleagues,
2012 [35]
Treatment interventions, biennial
mammography and CBE screening
interventions, awareness raising
To analyze the cost, effects and
cost-effectiveness of breast cancer
control interventions in Ghana, and
Both screening by clinical breast
examination and mass media
awareness raising seem
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Study quality
Table 4 summarizes the quality of the included studies,
as indicated by the percentage score. The quality of all
studies ranges from 23 to 86%. Studies by Ginsberg and
colleagues, Zelle and colleagues, and Bai and colleagues
had the highest total average scores, and these were all
modeling studies [27,35,42]. If items were not applicable
(NA) for a reviewed paper, the maximum obtainable
(domain) score was reduced with 2 points per item.
Studies generally scored poorly on the domain ‘estima-
tion of costs’, at an average 34% of the maximum obtainable
score across all studies. The average score for ‘study design’
was 73%, while the quality of the domains ‘estimation of
effectiveness’, ‘analysis’, and ‘interpretation of results’ was
scores as 70%, 51%, and 68%, respectively.
Study findings
As described earlier, most studies evaluated breast
cancer screening in combination with treatment. Studies in
Mexico, Poland, Turkey identified mammography screen-
ing as a cost-effective intervention [31,33,34,36], whereas
studies in India, Ghana and Egypt found other strategies
(such as CBE screening or mass-media awareness raising)
to be economically more attractive (Table 3) [26,30,35].
Sarvazyan and colleagues proposed another breast cancer
Table 3 Interventions compared, study objectives, and main study conclusions of reviewed articles (Continued)
interventions, palliative care interventions
vs. null scenario
identify the optimal mix of interventions
to maximize population health
economically attractive interventions
($1,299 and $1,364/DALY).
Mammography screening is not
cost-effective
Bai and colleagues,
2012 [42]
Radiotherapy vs. no radiotherapy after
surgery
To assess the cost-effectiveness of
additional radiotherapy for women
with early breast cancer after
breast-conserving surgery
In health resource-limited settings, the
addition of radiotherapy is a very
cost-effective strategy (−$420/ QALY)
in comparison with no-radio therapy
in women with early breast cancer
Arredondo and
colleagues, 1995 [43]
Case management costs for infrastructure,
human resources, laboratory, hospital stay,
drugs, mastectomy, disposable material,
curing material
To develop a system for monitoring
costs of case management for each
disease (breast cancer, cardiac calve
disease and enteritis and
bronchopneumonia)
Economic analyses hold important
information for decision-making
Boutayeb and
colleagues, 2010 [37]
Three chemotherapy regimes, AC, AC +
taxanes, AC + taxanes + trastuzumab
To evaluate the total cost of
chemotherapy in early stage
breast cancer
Moroccan health authorities need to
devote between US$13.3 to 28.6
million to treat women by
chemotherapy every year
Denewer and
colleagues, 2010 [26]
CBE-based screening with selective
mammography vs. no screening
To evaluate the disease pattern of
screen-detected cancers and determine
the effectiveness of CBE-based screening
CBE-based screening with selective
mammography is feasible, effective
and improves the results of breast
cancer management in Egypt
Guggisberg and
colleagues, 2011 [46]
On-site FNA clinic vs. shipping of specimens To assess the feasibility of an on-site
cytopathology clinic in a rural hospital
in Cameroon
Cytopathology (FNA) is a reliable
alternative for tissue diagnosis in
low-resource settings
Kobayashi, 1988 [44] Costs and performance of breast
echography in different institutions
To analyze the economics and cost
performance of breast echography in
various institutions
The best cost performance,
internationally, can be achieved by
mechanical and real-time electronic
linear scanners
Love and colleagues,
2002 [40]
Adjuvant oophorectomy and tamoxifen
vs. oophorectomy and tamoxifen for
recurrence after observation.
To evaluate costs, disease-free and
overall survival after surgical
oophorectomy and tamoxifen in
premenopausal Vietnamese women
with operable breast cancer
Vietnamese and Chinese women with
hormone receptor-positive operable
breast cancer benefit from adjuvant
treatment with surgical
oophorectomy and tamoxifen
Mousavi and
colleagues, 2008 [29]
Mammography screening in age groups
35 to 69 and 50 to 69 and no screening
To decide whether mammography
screening should be established in Iran
or whether other options are needed
Benefits of other policies than
mammography screening need
to be explored
Nasrinossadat and
colleagues, 2011 [47]
Methylene blue dye injections vs. wire
localization
To report experience in marking
nonpalpable breast masses by injection
of methylene dye
Marking with methylene blue dye is
a simple, effective and low-cost
method for localization of
nonpalpable breast masses
Thomas and
colleagues, 1999 [45]
FNA cytology vs. surgical tissue biopsy To assess the results and limitations of a
Nigerian FNA clinic
FNA cytology can help improve the
management and cost of care of
patients with palpable masses
CEA, cost-effectiveness analysis; CBE, clinical breast examination; DALY, disability-adjusted life year; FNA, fine needle aspiration; LMIC, low- and middle-income
country; NCD, noncommunicable disease; QALY, quality-adjusted life year; WHO, World Health Organization.
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Table 4 Summary of quality assessment and domain scores of reviewed studies
Authors Scored domains Summary scores
Study
design
Effectiveness
estimation
Cost
estimation
Analysis Interpretation
of results
Number of
items scored
Sum of
scores
Total
average
score
Groot and colleagues,
2006 [28]
Score granted 12 7 6 16 9 29 50 1.72
% of maximum
(domain) score
86% 88% 75% 89% 90% 86%
Okonkwo and
colleagues, 2008 [30]
Score granted 12 6 3 16 10 28 47 1.68
% of maximum
(domain) score
86% 100% 38% 100% 100% 84%
Munshi, 2009 [41] Score granted 7 7 0 1 4 21 19 0.90
% of maximum
(domain) score
50% 70% 0% 50% 40% 45%
Sarvazyan and
colleagues, 2008 [32]
Score granted 7 7 0 1 4 21 19 0.90
% of maximum
(domain) score
50% 70% 0% 50% 40% 45%
Fonseca and
colleagues, 2009 [38]
Score granted 14 6 1 13 10 28 44 1.57
% of maximum
(domain) score
100% 100% 13% 72% 100% 79%
Ginsberg and
colleagues, 2012 [27]
Score granted 12 8 8 18 10 29 52 1.79
% of maximum
(domain) score
86% 100% 75% 89% 100% 90%
Salomon and
colleagues, 2012 [31]
Score granted 12 6 5 14 8 29 45 1.55
% of maximum
(domain) score
86% 75% 63% 78% 80% 78%
Pakseresht and
colleagues, 2011 [48]
Score granted 7 1 4 3 5 15 20 1.33
% of maximum
(domain) score
88% 50% 50% 75% 63% 67%
Szynglarewicz and
Matkowski, 2011 [33]
Score granted 5 3 2 1 5 24 15 0.625
% of maximum
(domain) score
88% 50% 50% 75% 63% 33%
Yazihan and Yilmaz,
2006 [34]
Score granted 12 0 3 2 5 28 22 0.79
% of maximum
(domain) score
86% 0% 38% 13% 50% 40%
Bastani and Kiadaliri,
2012 [49]
Score granted 13 8 4 7 8 25 40 1.6
% of maximum
(domain) score
93% 100% 50% 70% 80% 80%
Liubao and
colleagues, 2009 [39]
Score granted 13 7 4 16 10 29 50 1.72
% of maximum
(domain) score
93% 88% 50% 89% 100% 86%
Astim, 2011 [36] Score granted 9 5 3 8 7 28 32 1.14
% of maximum
(domain) score
64% 63% 38% 50% 70% 57%
Zelle and colleagues,
2012 [35]
Score granted 14 7 7 14 10 29 52 1.79
% of maximum
(domain) score
100% 88% 88% 78% 100% 90%
Bai and colleagues,
2012 [42]
Score granted 13 8 5 18 8 29 52 1.79
% of maximum
(domain) score
93% 100% 63% 100% 80% 90%
Arredondo and
colleagues, 1995 [43]
Score granted 10 NA 1 0 7 18 18 1.00
% of maximum
(domain) score
71% NA 13% 0% 70% 50%
Score granted 12 4 4 1 6 25 27 1.08
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screening option: tactile imaging as an alternative to several
other interventions [32].
Studies evaluating treatment interventions typically
favored the novel interventions. Anastrozole was more
cost-effective than tamoxifen in a Brazilian study [38],
oophorectomy and tamoxifen after recurrence was
shown to be favorable in Vietnamese and Chinese patients
[40], additional radiotherapy after breast-conserving surgery
was very cost-effective in China [42], and chemotherapy
consisting of a docetaxel and cyclophosphamide regimen
was more attractive compared with an doxorubicin
and cyclophosphamide regimen also in Chinese patients
[39]. There was only one study with a negative sug-
gestion for the novel and more costly intervention
docetaxel, doxorubicin, cyclophosphamide, as compared
with the more conventional 5-fluorouracil, doxorubicin,
dyclophosphamide regime [49].
Studies that only assessed costs and did not include
effectiveness estimates, reported on costs of breast cancer
for patient management in Brazil (US$1,646 per patient)
[43], and the costs of patient expenditure (US$242 per
patient) in India [48].
The three studies evaluating diagnostic interventions
demonstrated the economic attractiveness of inexpensive
interventions; that is, fine-needle aspiration cytology and
methylene blue dye injections [45-47]. These interventions
could be especially relevant for diagnosing breast cancer
in rural settings and settings with low resources.
Discussion
This study shows that there is limited economic evidence
on breast cancer control in LMICs. Only 24 economic
evaluation studies were found in this review, and their qual-
ity was generally poor. Furthermore, the study populations
were very diverse, as most studies examined different kinds
of screening and therapeutic interventions in various age
and risk groups. Owing to this poor availability, quality, and
comparability, we conclude that the economic evidence
base to guide strategies for breast cancer in LMICs is
currently insufficient.
Our review raises a few discussion points. First, there
is mixed evidence on the economic attractiveness of
mammography screening. Studies in Mexico, Poland and
Turkey demonstrate the intervention to be cost-effective,
whereas studies in India, Ghana, and Egypt suggests
that other forms of screening – for example, by CBE –
provide more value for money. The evidence base is too
small to generalize these findings to other LMICs, and
to draw general conclusions. Also, most of the studies
evaluating therapeutic interventions seem to favor the
more novel – and often more expensive – therapy.
These findings may be explained by many reasons,
including the higher effectiveness of the novel interven-
tions but possibly also the association between funding
sources and pro-industry conclusions [50].
Second, in general, we found that the quality of the
reviewed articles was poor. The majority of studies failed
Table 4 Summary of quality assessment and domain scores of reviewed studies (Continued)
Boutayeb and
colleagues, 2010 [37]
% of maximum
(domain) score
86% 50% 50% 13% 60% 54%
Denewer and
colleagues, 2010 [26]
Score granted 10 4 0 2 5 25 21 0.84
% of maximum
(domain) score
71% 50% 0% 20% 50% 42%
Guggisberg and
colleagues, 2011 [46]
Score granted 3 6 2 1 5 25 24 0.96
% of maximum
(domain) score
21% 75% 25% 13% 50% 35%
Kobayashi, 1988 [44] Score granted 4 4 1 NA 3 19 12 0.63
% of maximum
(domain) score
29% 67% 13% NA 30% 32%
Love and colleagues,
2002 [40]
Score granted 9 6 1 10 8 27 34 1.26
% of maximum
(domain) score
64% 100% 13% 63% 80% 63%
Mousavi and
colleagues, 2008 [29]
Score granted 5 1 0 1 3 22 10 0.45
% of maximum
(domain) score
36% 25% 0% 13% 30% 23%
Nasrinossadat and
colleagues, 2011 [47]
Score granted 75 5 0 0 5 25 17 0.68
% of maximum
(domain) score
50% 63% 0% 0% 50% 34%
Thomas and
colleagues, 1999 [45]
Score granted 7 4 0 0 6 21 17 0.81
% of maximum
(domain) score
50% 67% 0% 0% 60% 41%
Total average domain score (%) 73% 70% 34% 51% 68%
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to score at least 50% on every domain (‘study design’,
‘estimation of effectiveness’, ‘estimation of costs’, ‘analysis’,
and ‘interpretation of results’). These domain scores
further show that most emphasis was given to the design
of the studies and the interpretation of results, whereas
costs, in particular, were poorly evaluated. This calls for
better adherence of studies to methodological standards for
economic analyses, or the development of such standards
specifically for breast cancer research. Future studies could
be improved by using a checklist, and through transparent
reporting of the items in checklists [25,51].
Third, the current evidence base leaves many LMICs
with the difficult task of extrapolating results from other
countries. The transferability of economic evaluations
across countries is complicated, as clinical practice patterns,
healthcare systems, and cultural and ethical practices differ
across countries [52,53]. Standardized ways of adopting
economic evaluations, with the help of available checklists
and guidelines [24,25,51,54-58], may improve this lack of
transferability. Alternatively, modeling studies could play an
important role in extrapolating results from one context to
another. Modeling studies, however, rely on the availability
of costing and effectiveness data, and this emphasizes the
need for more primary data collection on these aspects
in LMICs. With data from such studies, researchers
would not have to continue to rely on sensitivity analyses
or extrapolating cost estimates from data in HICs. National
cancer registries, mortality databases, hospital registries,
and accessible publications would be essential for providing
such information [59].
Fourth, and closely related, we generally advocate the
use of modeling studies in the economic analysis of
breast cancer control in LMICs. In addition to their use
in the extrapolation of study findings, they generally
appeared to be of high quality, are sufficiently flexible to
include important methodological characteristics such as
adequate time horizon, and seem also appropriate to evalu-
ate a broad array of interventions across different groups.
Fifth, the most adopted type of economic evaluation was
cost-effectiveness analysis, using a healthcare perspective
and life years saved as the primary outcome. Although
cost-effectiveness analyses using a healthcare perspective
contribute very important information, productivity losses
for patients suffering from breast cancer – and most
probably other NCDs – can be substantial [60,61]. So
far, there is no methodological consensus on estimating
productivity loss and the cost of illness can vary greatly
between different costing approaches (for example,
human capital approach vs. friction cost approach)
and also between gender, age and the type of job of patients
[62]. Further research should account for economic and
social characteristics of the population under study, and
should try to investigate productivity losses. Additionally,
life years saved may be a less appropriate outcome when
palliative or preventive interventions are investigated, and
the use of disability-adjusted or quality-adjusted life years
may be more appropriate.
Sixth, there is currently very little economic evidence
on less established interventions such as tactile imaging,
awareness raising, CBE screening, or preventive and
palliative interventions. Economic studies, especially in
LMICs, should aim to evaluate these interventions more
often (and thereby including broad target populations)
as they have the potential to be economically attractive
[26,30,32,35].
Finally, guidance in decision-making and recommenda-
tions for implementation are generally underemphasized in
economic evaluations. By reflecting on the health system
characteristics of the particular country and considering
them in implementation recommendations, economic
evaluations could improve their use in breast cancer
policy development.
Our study has a number of limitations. Primarily, the
number of articles reviewed is very limited, possibly the
result of our search strategy. Besides a possible publica-
tion bias – studies with negative outcomes are less likely
to be published – we searched only for articles published
in English. This may explain the relatively small number
of articles found, for instance, from Spanish-speaking
regions or from countries where there is less emphasis
on publishing research (for example, in Africa). Also, the
studies included in our review vastly differed with regard
to their methodology, objectives, characteristics, and
study populations and hence are difficult to compare. In
addition, our quality assessment of the reviewed articles
was based on a checklist that gives highest scores to a
full reporting of all domains. However, short reports in
the form of, for example, editorials may not include all
these details but may nevertheless be valid for the goals
they serve. Hence, the scores for these studies should be
interpreted with caution.
Conclusions
To conclude, our findings indicate that research on the
costs and cost-effectiveness of breast cancer control in
LMICs is still in its infancy. The limited evidence base
suggests that screening strategies may be economically
attractive in LMICs – yet there is very little evidence to
provide specific recommendations (on screening by
mammography vs. CBE, the frequency of screening, or
the target population). These results demonstrate the
need for more economic analysis that are uniform, of
better quality, cover a comprehensive set of interventions
and result in clear policy recommendations.
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